peterschreiber.media/iStock via Getty Images
Regulus Therapeutics (NASDAQ:RGLS) shares tumbled 24% Wednesday after the biotech company reported results from a study analysis for its ADPKD program and issued a regulatory update.
Regulus (NASDAQ:RGLS) said topline results were positive from an interim analysis of the